CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Cambien, Béatrice ^a,b   Richard Fiardo, Peggy ^a,b   Karimdjee, Babou F ^a,b,c   Martini, Violette ^a,b   Ferrua, Bernard ^b   Pitard, Bruno ^b,d   Schmid Antomarchi, Heidy ^a,b   Schmid Alliana, Annie ^a,b  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b INSERM   (France)

^c Clinique St Jean   (France)

^d In Cell Art   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; DNA VACCINE; IMMUNOGLOBULIN G ANTIBODY; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RANTES; AMIDE; NEUTRALIZING ANTIBODY; QUATERNARY AMMONIUM DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CARCINOMATOSIS; CELL COUNT; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; COLORECTAL CARCINOMA; DNA IMMUNIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; LIVER METASTASIS; LUNG METASTASIS; MOUSE; NONHUMAN; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR IMMUNITY; ANIMAL; CELL MOTION; CELL STRAIN HT29; CHO CELL; COLORECTAL TUMOR; CRICETULUS; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; HAMSTER; IMMUNOLOGY; LEUKOCYTE; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TREATMENT OUTCOME;

AMIDES; ANIMALS; ANTIBODIES, NEUTRALIZING; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CCL5; CHO CELLS; COLORECTAL NEOPLASMS; CRICETINAE; CRICETULUS; DISEASE PROGRESSION; FEMALE; HT29 CELLS; HUMANS; LEUKOCYTES; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; QUATERNARY AMMONIUM COMPOUNDS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, CCR5; TREATMENT OUTCOME;

EID: 83755183659     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028842     Document Type: Article

References (48)

1. Mueller MM, Fusenig NE, (2004) Friends or foes- bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4 (11): 839-49.
2. Bhowmick NA, Neilson EG, Moses HL, (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432 (7015): 332-7.
3. Tlsty TD, Coussens LM, (2006) Tumor stroma and regulation of cancer development. Annu Rev Pathol 1: 119-50.
4. Ito M, Yoshida K, Kyo E, Ayhan A, Nakayama H, et al. (1990) Expression of several growth factors and their receptor genes in human colon carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 59 (3): 173-8.
5. De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, et al. (1998) Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 28 (4): 971-9.
6. Hemming AW, Davis NL, Kluftinger A, Robinson B, Quenville NF, et al. (1992) Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 51 (3): 147-52.
7. Kuwai T, Kitadai Y, Tanaka S, Onogawa S, Matsutani N, et al. (2003) Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer 105 (2): 176-81.
8. Gschwind A, Fischer OM, Ullrich A, (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4 (5): 361-70.
9. Balkwill F, (2004) Cancer and the chemokine network. Nat Rev Cancer 4 (7): 540-50.
10. Erreni M, Bianchi P, Laghi L, Mirolo M, Fabbri M, et al. (2009) Expression of chemokines and chemokine receptors in human colon cancer. Methods Enzymol 460: 105-21.
11. Cambien B, Karimdjee BF, Richard-Fiardo P, Bziouech H, Barthel R, et al. (2009) Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer 100 (11): 1755-64.
12. Pradelli E, Karimdjee-Soilihi B, Michiels JF, Ricci JE, Millet MA, et al. (2009) Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer 125 (11): 2586-94.
13. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, et al. (1999) Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 59 (18): 4681-7.
14. Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA, (2006) Inflammation, genetic polymorphisms in proinflammatory genes TNF-α, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 15 (4): 726-31.
15. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K, (2006) Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder. Gynecol Oncol 102 (3): 542-5.
16. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, et al. (2001) Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 7 (2): 285-9.
17. Kim HK, Song KS, Park YS, Kang YH, Lee YJ, et al. (2003) Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 39 (2): 184-91.
18. Vaday GG, Peehl DM, Kadam PA, Lawrence DM, (2006) Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66 (2): 124-34.
19. Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai EL, et al. (2006) The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 12 (15): 4474-80.
20. Sugasawa H, Ichikura T, Kinoshita M, Ono S, Majima T, et al. (2008) Gastric cancer cells exploit CD4+ cell-derived CCL5 for their growth and prevention of CD8+ cell-involved tumor elimination. Int J Cancer 122 (11): 2535-41.
21. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449 (7162): 557-63.
22. Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, et al. (2009) Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 182 (3): 1746-55.
23. Zhang X, Haney KM, Richardson AC, Wilson E, Gewirtz DA, et al. (2010) Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents. Bioorg Med Chem Lett 20 (15): 4627-30.
24. Horst D, Budczies J, Brabletz T, Kirchner T, Hlubek F, (2009) Invasion associated up-regulation of nuclear factor kappaB target genes in colorectal cancer. Cancer 115 (21): 4946-58.
25. McIlroy D, Barteau B, Cany J, Richard P, Gourden C, et al. (2009) DNA/amphiphilic block copolymer nanospheres promote low-dose DNA vaccination. Mol Ther 17 (8): 1473-81.
26. Cany J, Barteau B, Tran L, Gauttier V, Archambeaud I, et al. (2010) AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice. J Hepatol 54 (1): 115-21.
27. Vitale S, Cambien B, Karimdjee BF, Barthel R, Staccini P, et al. (2007) Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer. Gut 56 (3): 365-72.
28. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, et al. (1999) A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 96 (10): 5698-703.
29. Marella M, Chabry J, (2004) Neurons and astrocytes respond to prion infection by inducing microglia recruitment. J Neurosci 24 (3): 620-7.
30. Wehler TC, Frerichs K, Graf C, Drescher D, Schimanski K, et al. (2008) PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy. Oncol Rep 19 (3): 697-704.
31. Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H, et al. (2005) Chemokines in tumor progression and metastasis. Cancer Sci 96 (6): 317-22.
32. Elenbaas B, Weinberg RA, (2001) Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 10;264 (1): 169-84.
33. Bailey C, Negus R, Morris A, Ziprin P, Goldin R, et al. (2007) Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis 24 (2): 121-30.
34. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L, (1992) The origin and function of tumor-associated macrophages. Immunol Today 13 (7): 265-70.
35. Grimminger F, Schermuly RT, Ghofrani HA, Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 9 (12): 956-70.
36. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, et al. (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295 (1): 139-45.
37. Kim R, Emi M, Arihiro K, Tanabe K, Uchida Y, et al. (2005) Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer 103 (9): 1800-9.
38. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, et al. (2006) Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol 169 (6): 2054-65.
39. Kuwai T, Nakamura T, Sasaki T, Kitadai Y, et al. (2008) Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin Exp Metastasis 25 (4): 477-89.
40. Kaplan CD, Kruger JA, Zhou H, Luo Y, Xiang R, et al. (2006) A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma. Vaccine 24 (47-48): 6994-7002.
41. Coltrera MD, Wang J, Porter PL, Gown AM, (1995) Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res 55 (12): 2703-8.
42. Bhardwaj B, Klassen J, Cossette N, Sterns E, Tuck A, et al. (1996) Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. Clin Cancer Res 2 (4): 773-82.
43. Kawai T, Hiroi S, Torikata C, (1997) Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest 77 (5): 431-6.
44. Singer CF, Hudelist G, Lamm W, Mueller R, Czerwenka K, et al. (2004) Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocr Relat Cancer 11 (4): 861-9.
45. Ostman A, Heldin CH, (2001) Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res 80: 1-38.
46. Risau W, Drexler H, Mironov V, Smits A, Siegbahn A, et al. (1992) Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7 (4): 261-6.
47. Ostman A, (2004) PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15 (4): 275-86.
48. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D, (2004) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111 (9): 1287-95.